Supply chain leaders love to talk about their push for “digitization” of key processes. But their hiring patterns aren’t always lining up with that rhetoric.

Already in 2025, we've seen the direct and indirect impacts of climate change on the price and availability of essential foods.

U.S.-based companies are also likely to suffer because of reciprocal tariffs imposed by America’s trading partners in retaliation, threatening profit from exports. 

Don’t expect the Trump tariffs to trigger a boom in domestic manufacturing in the U.S. — or an end to the growth of “nearshored” production capacity in Mexico.

Prices will rise, maybe wages will too. The question is whether Trump’s new tariff regime will pay off. 

Ending de minimis requirements altogether could mean more paperwork, longer processing times, and higher costs for everyone from shippers to consumers.

Some argue that Trump is simply using threats of injurious trade penalties in order to win smaller, different concessions. Others see a far more dramatic agenda at play.

Can the U.S. pharmaceutical supply chain come home — or, at least, get closer to it?

Although Trump has repeatedly said he wants the U.S. to retake the Panama Canal, his actual goals could fall well short of that. 

Leaders announced the reintroduction of the Railway Safety Act, which was first proposed in Congress the month after the derailment in 2023, but died in committee months later.